The content on this site is intended for healthcare professionals only
Dr Andreas du Bois presents data on a phase III clinical trial in women with advanced ovarian cancer at the 2013 ASCO Annual Meeting in Chicago.
The Study found that treatment with the oral targeted drug pazopanib following initial successful chemotherapy extends disease-free survival by an average of 5.6 months, compared to placebo.
Advanced ovarian cancer is an aggressive disease with a cure rate of only 20-25 percent. Despite successful initial treatment with surgery and chemotherapy, about 70 percent of patients with advanced ovarian cancer experience a relapse, half in the first year. Upon relapse, patients have to resume aggressive treatments. At this time, there is no test available to predict a patient’s risk for relapse, so a maintenance therapy such as this one would be used for most patients.
ESMO 2025: Latest developments in endometrial cancer
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer
